CN113498864A - Camel milk polypeptide nano-particle oral liquid and preparation method thereof - Google Patents
Camel milk polypeptide nano-particle oral liquid and preparation method thereof Download PDFInfo
- Publication number
- CN113498864A CN113498864A CN202110687025.3A CN202110687025A CN113498864A CN 113498864 A CN113498864 A CN 113498864A CN 202110687025 A CN202110687025 A CN 202110687025A CN 113498864 A CN113498864 A CN 113498864A
- Authority
- CN
- China
- Prior art keywords
- camel milk
- oral liquid
- milk polypeptide
- weight
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000020248 camel milk Nutrition 0.000 title claims abstract description 181
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 181
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 171
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 164
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 120
- 239000007788 liquid Substances 0.000 title claims abstract description 99
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000012071 phase Substances 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 30
- 239000002562 thickening agent Substances 0.000 claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 27
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 27
- 239000003381 stabilizer Substances 0.000 claims abstract description 27
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 26
- 239000003765 sweetening agent Substances 0.000 claims abstract description 26
- 238000003756 stirring Methods 0.000 claims description 35
- 235000006708 antioxidants Nutrition 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 28
- 239000003755 preservative agent Substances 0.000 claims description 28
- 230000002335 preservative effect Effects 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
- 229920000053 polysorbate 80 Polymers 0.000 claims description 11
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 238000009210 therapy by ultrasound Methods 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 7
- 239000004386 Erythritol Substances 0.000 claims description 7
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 7
- 235000015165 citric acid Nutrition 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 235000019414 erythritol Nutrition 0.000 claims description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 7
- 229940009714 erythritol Drugs 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 229960002969 oleic acid Drugs 0.000 claims description 7
- 239000004302 potassium sorbate Substances 0.000 claims description 7
- 235000010241 potassium sorbate Nutrition 0.000 claims description 7
- 229940069338 potassium sorbate Drugs 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 235000013793 astaxanthin Nutrition 0.000 claims description 6
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 6
- 229940022405 astaxanthin Drugs 0.000 claims description 6
- 239000001168 astaxanthin Substances 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229940074045 glyceryl distearate Drugs 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 229940067631 phospholipid Drugs 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- 239000000845 maltitol Substances 0.000 claims description 5
- 235000010449 maltitol Nutrition 0.000 claims description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 5
- 229940035436 maltitol Drugs 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 229920001993 poloxamer 188 Polymers 0.000 claims description 5
- 229940044519 poloxamer 188 Drugs 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 235000013616 tea Nutrition 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 229960005150 glycerol Drugs 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 229940023476 agar Drugs 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 229960004106 citric acid Drugs 0.000 claims description 3
- 229940031016 ethyl linoleate Drugs 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 229960003885 sodium benzoate Drugs 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 29
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 230000001603 reducing effect Effects 0.000 abstract description 16
- 235000009508 confectionery Nutrition 0.000 abstract description 12
- 235000019640 taste Nutrition 0.000 abstract description 8
- 238000001556 precipitation Methods 0.000 abstract description 6
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 34
- 238000001514 detection method Methods 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000002047 solid lipid nanoparticle Substances 0.000 description 8
- 239000012888 bovine serum Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 6
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 6
- 102000014171 Milk Proteins Human genes 0.000 description 6
- 108010011756 Milk Proteins Proteins 0.000 description 6
- 102000004139 alpha-Amylases Human genes 0.000 description 6
- 108090000637 alpha-Amylases Proteins 0.000 description 6
- 229940024171 alpha-amylase Drugs 0.000 description 6
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000001935 peptisation Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to camel milk polypeptide nano-particle oral liquid with a blood sugar reducing effect and a preparation method thereof. The composition contains camel milk polypeptide, oil phase, emulsifier, stabilizer, antioxidant, thickener, sweetener, antiseptic, etc. The camel milk polypeptide nanoparticle oral liquid is transparent and uniform in color, colorless, free of pungent peculiar smell, soft and refreshing in taste, slightly sweet and sweet, uniform in tissue, free of layering and precipitation, and has a good effect of reducing blood sugar.
Description
[ technical field ] A method for producing a semiconductor device
The invention belongs to the technical field of functional foods. More specifically, the invention relates to camel milk polypeptide nano-particle oral liquid and a preparation method of the camel milk polypeptide nano-particle oral liquid.
[ background of the invention ]
The existing research finds that the aim of reducing blood sugar can be achieved by frequently eating natural food with the blood sugar reducing effect by the diabetic patients and matching with the treatment of medicines, and meanwhile, the toxic and side effects of the traditional medicines can be reduced. The camel milk protein can generate bioactive peptide with blood sugar reducing effect after hydrolysis, and can effectively improve the blood sugar condition of organism. Therefore, the camel milk polypeptide has important significance in developing more updated functional products.
Diabetes is a metabolic disease mainly characterized by hyperglycemia, and the main root of the disease is excessive blood sugar concentration, and the control and reduction of blood sugar are the only way to treat diabetes. Therefore, there is a need to develop functional foods or medicines, especially natural bioactive peptides, with low toxic and side effects and with hypoglycemic effects for the prevention and adjuvant treatment of diabetes. The camel milk has high nutritive value, and can provide essential nutrients for human body. In addition, it has different functional characteristics and health care curative effect, so that it becomes a very high-quality milk source. The camel milk has pure natural bioactive factors and medicinal components, and the content of protective protein of the camel milk is higher than that of other ruminant milk. The primary structure of camel milk protein contains amino acid sequences of many active peptides, which are released and function only through a certain hydrolysis. The camel milk protein can generate bioactive peptide with the function of reducing blood sugar through hydrolysis, and can effectively improve the health condition of organisms. However, most camel milk polypeptides are degraded and inactivated by gastrointestinal proteases and peptidases, and have low bioavailability. The solid lipid nanoparticles SLN (solid lipid nanoparticles) are solid colloidal particle drug delivery systems prepared by taking solid or natural synthetic lipids as carrier materials and wrapping or embedding drugs in a lipid core, the lipophilic skeleton structure of the SLN can prevent the drugs from being rapidly released, and the solid lipids have strong cell membrane permeability. The drug is encapsulated in the SLN, so that the purposes of controlling the drug release and improving the bioavailability can be achieved. Therefore, the camel milk polypeptide nanoparticles prepared by wrapping the peptides in the solid lipid nanoparticle embedding technology can ensure that the peptides are better absorbed by a human body and avoid the damage of gastrointestinal digestive juice to the peptides. In addition, the oral liquid has better medicine absorption effect compared with oral medicines, has less medicine residue than the oral medicine residue, and has the characteristics of easy absorption, small volume, convenient carrying and storage. Therefore, the camel milk polypeptide nano-particles are prepared into the oral liquid with the nutrition supplementing effect, and the blood sugar can be effectively reduced.
Aiming at the technical defects in the prior art, the inventor finally completes the invention on the basis of summarizing the prior art and a large amount of experimental research.
[ summary of the invention ]
[ problem to be solved ]
The invention aims to provide camel milk polypeptide nano-particle oral liquid.
The invention also aims to provide a preparation method of the camel milk polypeptide nanoparticle oral liquid.
[ solution ]
The invention is realized by the following technical scheme.
The invention relates to camel milk polypeptide nano-particle oral liquid.
The camel milk polypeptide nano-particle oral liquid comprises the following components: in parts by weight
According to a preferred embodiment of the invention, the camel milk polypeptide nanoparticle oral liquid comprises the following components: in parts by weight
According to another preferred embodiment of the invention, the camel milk polypeptide is a camel milk polypeptide which is obtained by carrying out enzymolysis and ultrafiltration on camel milk and has a molecular weight of less than 3 Kda.
According to another preferred embodiment of the invention, the oily phase is one or more oily phases selected from glyceryl distearate, ethyl linoleate, glyceryl monostearate or oleic acid.
According to another preferred embodiment of the invention, said emulsifier is one or more emulsifiers selected from tween 80, poloxamer 188, phospholipids or polysorbate 80.
According to another preferred embodiment of the invention, the stabilizer is one or more stabilizers selected from xanthan gum, guar gum, carrageenan or agar.
According to another preferred embodiment of the invention, said thickening agent is one or more thickening agents selected from the group consisting of sodium carboxymethylcellulose, pectin, gelatin or acacia.
According to another preferred embodiment of the present invention, the antioxidant is one or more antioxidants selected from the group consisting of vitamin E, astaxanthin, tea polyphenol or propyl gallate.
According to another preferred embodiment of the present invention, the sweetener is one or more selected from erythritol, maltitol, xylitol or glycerol.
According to another preferred embodiment of the present invention, the preservative is one or more preservatives selected from potassium sorbate, sodium benzoate, ethyl paraben or citric acid.
The invention also relates to a preparation method of the camel milk polypeptide nano-particle oral liquid.
The preparation method comprises the following preparation steps:
A. preparing camel milk polypeptide nanoparticles:
dissolving 0.012-0.020 part by weight of camel milk polypeptide in 1.5-2.5 parts by weight of mixed solvent consisting of ammonia water and absolute ethyl alcohol according to a weight ratio of 1:0.5 to obtain a camel milk polypeptide solution; heating 0.002-2.0 parts by weight of oil phase to 80 ℃, adding the camel milk polypeptide solution, uniformly mixing, heating at 75-80 ℃ to remove ammonia and ethanol, adding 1.0-2.5 parts by weight of emulsifier, stirring and uniformly mixing at 75-80 ℃, homogenizing for 6-8 min by using a homogenizing device at a homogenizing speed of 8000-12000 r/min, standing, and performing ultrasonic treatment by using an ultrasonic probe device to obtain the camel milk polypeptide nanoparticles;
B. preparation of an aqueous mixture
Mixing 0.01-0.05 part by weight of stabilizer, 0.01-0.05 part by weight of antioxidant, 0.01-0.05 part by weight of thickener, 0.01-0.05 part by weight of sweetener, 0.01-0.05 part by weight of preservative and deionized water which is supplemented to 100 parts by weight of the total amount, stirring and dissolving, homogenizing for 6-8 min under the condition that the homogenizing speed is 8000-12000 r/min, and standing to obtain an aqueous phase mixture;
C. mixing
And C, pouring the camel milk polypeptide nano-particles obtained in the step A into the water phase mixture obtained in the step B under the stirring condition, and continuously stirring for 2-5 minutes at the stirring speed of 15-25 r/min to obtain the camel milk polypeptide nano-particle oral liquid.
The present invention will be described in more detail below.
The inventor finds that camel milk polypeptide with the molecular weight less than 3Kda obtained by enzymolysis and ultrafiltration treatment of camel milk has the function of reducing blood sugar, and can effectively prevent and assist in treating diabetes. The inventor also researches and discovers that most camel milk polypeptides are degraded and inactivated by gastrointestinal tract protease and peptidase, and the bioavailability is low. Therefore, the camel milk polypeptide is wrapped in the camel milk polypeptide by adopting a solid lipid nanoparticle embedding technology when the camel milk polypeptide nanoparticle oral liquid is prepared, so that the better peptide absorption of a human body can be ensured, the solubility of the peptide is increased, and the damage of gastrointestinal digestive juice to the peptide is avoided.
The invention relates to camel milk polypeptide nano-particle oral liquid.
The camel milk polypeptide nano-particle oral liquid comprises the following components: in parts by weight
According to the invention, the main functions of the camel milk polypeptide in the camel milk polypeptide nano-particle oral liquid are to effectively reduce blood sugar and prevent diabetes; the camel milk polypeptide is camel milk polypeptide with the molecular weight of less than 3Kda, which is obtained by carrying out enzymolysis and ultrafiltration treatment on camel milk. The preparation method of the camel milk polypeptide used by the invention comprises the following steps:
centrifuging fresh camel milk at 8000r/min and 4 deg.C for 20min, and removing upper layer fat. Placing defatted camel milk in a dialysis bag, dialyzing for 24h at dialysis temperature of 4 deg.C with phosphate buffer as external liquid, and removing impurities. And then placing the camel milk after impurity removal into a freezing box to pre-freeze for 24h at the temperature of minus 80 ℃, then placing into a vacuum freeze dryer, and drying under the conditions of the temperature of minus 50 ℃ and the pressure of 1Pa to obtain the camel milk protein powder. After the dried camel milk protein is recovered by 10% (W/V) of substrate concentration, the camel milk protein powder is subjected to enzymolysis by selecting compound protease sold by Beijing Solebao science and technology Limited under the enzymolysis conditions that the enzyme dosage is 6% by weight, the enzymolysis temperature is 55 ℃, the enzymolysis pH is 6.5 and the enzymolysis time is 4 hours. Inactivating enzyme at 90 deg.C for 20min after hydrolysis, cooling, centrifuging at rotation speed of 4000r/min and temperature of 4 deg.C for 10min, and separating the obtained supernatant with 3kDa ultrafilter at rotation speed of 4000r/min and temperature of 4 deg.C for 20 min. And (3) freeze-drying the obtained ultrafiltrate with the Kda below 3 at the temperature of minus 50 ℃ and under the pressure of 1Pa to obtain the camel milk polypeptide.
Of course, the camel milk polypeptide used in the present invention can also be prepared by the method described in the comparative analysis of the antioxidant activity of camel milk and cow milk whey protein and the application research thereof, specifically refer to the literature: haichaoli, entitled "comparative analysis of antioxidant activity of Camel milk and milk whey protein and research on its application", master academic thesis of university of inner Mongolia agriculture, 2020, 06 months.
According to the invention, the main function of the oil phase in the camel milk polypeptide nano-particle oral liquid is that the oil phase is used as a framework material to wrap or clamp camel milk polypeptide in a lipoid core to prepare camel milk polypeptide nano-particles;
the oil phase is one or more oil phases selected from glyceryl distearate, ethyl linoleate, glyceryl monostearate or oleic acid. The oil phase used in the present invention is a product currently commercially available, for example, a product sold under the trade name of distearoyl glyceride by national group chemical Co., Ltd, a product sold under the trade name of linoleic acid ethyl ester by Wuhan Fuxin Yuan science Co., Ltd, a product sold under the trade name of stearyl glyceride by Hebei Lihua Bioscience Co., Ltd, and a product sold under the trade name of oleic acid by national group chemical Co., Ltd.
Of course, other oil phases having the above-mentioned effects can be used in the present invention, but they do not adversely affect the quality and effects of the camel milk polypeptide nanoparticle oral liquid of the present invention, and these oil phases can be used in the present invention and are within the scope of the present invention.
According to the camel milk polypeptide nano-particle oral liquid, the emulsifier mainly has the effects of reducing the interfacial surface tension of the emulsion to stably disperse nano-particles and effectively preventing the particles from agglomerating;
the emulsifier is one or more selected from Tween 80, poloxamer 188, phospholipid or polysorbate 80. The emulsifier used in the present invention is a product currently marketed, for example, a product sold under the trade name Tween 80 by national pharmaceutical group chemical Co., Ltd, a product sold under the trade name poloxamer 188 by Hubei Xingchengkang chemical technology Co., Ltd, and a product sold under the trade name phospholipid by Beijing derived Huamei phospholipid Co., Ltd.
Of course, other emulsifiers having the above-mentioned effects can be used in the present invention, as long as they do not adversely affect the quality and the effects of the camel milk polypeptide nanoparticle oral liquid of the present invention, and such emulsifiers can be used in the present invention and are also within the scope of the present invention.
According to the invention, the main effect of the stabilizing agent in the camel milk polypeptide nano-particle oral liquid is to increase the stability of the oral liquid;
the stabilizer is one or more of xanthan gum, guar gum, carrageenan or agar. The stabilizer used in the present invention is a product currently marketed, such as a product sold under the trade name xanthan gum by Xinjiang club amino acid GmbH, a product sold under the trade name guar gum by Hebeili Hua Biotech Ltd, a product sold under the trade name carrageenan by Zhengzhou Yu and food additives Ltd.
Of course, other stabilizers having the above-mentioned effects can be used in the present invention, as long as they do not adversely affect the quality and effects of the camel milk polypeptide nanoparticle oral liquid of the present invention, and such stabilizers can be used in the present invention and are within the scope of the present invention.
According to the invention, the main function of the antioxidant in the camel milk polypeptide nano-particle oral liquid is to improve the stability of the oral liquid and prolong the storage period;
the antioxidant is one or more antioxidants selected from vitamin E, astaxanthin, tea polyphenol or propyl gallate. The antioxidant used in the present invention is a product currently marketed, for example, a product sold under the trade name vitamin E by Chongqing power Macro Fine chemical Co., Ltd, a product sold under the trade name astaxanthin by Shaanxi Ming Biotech Co., Ltd, and a product sold under the trade name tea polyphenol by Jiangsu Caesawei Biotech Co., Ltd.
Of course, other antioxidants having the above-mentioned effects can be used in the present invention, as long as they do not adversely affect the quality and the effects of the camel milk polypeptide nanoparticle oral liquid of the present invention, and such antioxidants can be used in the present invention and are within the scope of the present invention.
According to the invention, the main function of the thickening agent in the camel milk polypeptide nanoparticle oral liquid is to enable the oral liquid to form a specific shape and increase the viscosity of the oral liquid;
the thickening agent is one or more thickening agents selected from sodium carboxymethylcellulose, pectin, gelatin or acacia. The thickeners used in the present invention are all commercially available products such as those sold under the trade name sodium carboxymethylcellulose by Chongqing force Macro Fine chemical Co., Ltd, those sold under the trade name pectin by Hebei Runfu Biotech Co., Ltd, and those sold under the trade name gelatin by Hebei Jijie Biotech Co., Ltd.
Of course, other thickeners having the above-mentioned effects can be used in the present invention, as long as they do not adversely affect the quality of the camel milk polypeptide nanoparticle oral liquid of the present invention and the effects thereof, and such thickeners can be used in the present invention and are within the scope of the present invention.
According to the invention, the main function of the sweetening agent in the camel milk polypeptide nano-particle oral liquid is to improve the taste of the oral liquid;
the sweetener is one or more selected from erythritol, maltitol, xylitol or glycerol. The sweetener used in the present invention is a product currently marketed, for example, a product sold under the trade name erythritol by Shandong Futian pharmaceutical Co., Ltd, a product sold under the trade name maltitol by Chengdu Honghun Biotech Co., Ltd, and a product sold under the trade name xylitol by Hebei Lihua Biotech Co., Ltd.
Of course, other sweeteners having the above-mentioned effects can be used in the present invention, but they do not adversely affect the quality and effects of the camel milk polypeptide nanoparticle oral liquid of the present invention, and such sweeteners can be used in the present invention and are within the scope of the present invention.
According to the invention, the main function of the preservative in the camel milk polypeptide nanoparticle oral liquid is to stabilize the product against microorganisms and have a sufficiently long shelf life;
the preservative is one or more preservatives selected from potassium sorbate, sodium benzoate, ethyl p-hydroxybenzoate or citric acid. The preservatives used in the present invention are all products currently marketed, for example, by Weifang Yinxuan practice Co., Ltd under the trade name of potassium sorbate, by Hebei Runzhong Biotech Co., Ltd under the trade name of sodium benzoate, and by Chengdu Wan Hongrun Biotech Co., Ltd under the trade name of ethyl p-hydroxybenzoate.
Of course, other preservatives having the above-mentioned effects can be used in the present invention, as long as they do not adversely affect the quality and the effects of the camel milk polypeptide nanoparticle oral liquid of the present invention, and such preservatives can be used in the present invention and are also within the scope of the present invention.
In the invention, when the contents of the oil phase, the emulsifier, the stabilizer, the antioxidant, the thickener, the sweetener and the preservative are in the range, if the content of the camel milk polypeptide component is less than 0.012 parts, the embedding rate of the camel milk polypeptide nano-particles is low, and the oral liquid has poor blood sugar reducing effect; if the content of the camel milk polypeptide component is higher than 0.020 parts, the stability of the camel milk polypeptide nanoparticles is poor, and excessive camel milk polypeptides can be lost into a water phase; therefore, the content of the camel milk polypeptide component is 0.012 to 0.020 parts, preferably 0.014 to 0.018 parts;
similarly, when the contents of camel milk polypeptide, emulsifier, stabilizer, antioxidant, thickener, sweetener and preservative are in the above range, if the content of oil phase component is less than 0.002 parts, the camel milk polypeptide is difficult to form into nanoparticles; if the content of the oil phase components is higher than 2.0 parts, the camel milk polypeptide nanoparticles are easy to flocculate, and the interaction between the emulsions is influenced; therefore, it is appropriate that the content of the oil phase component is 0.002 to 2.0 parts, preferably 0.012 to 1.8 parts;
when the contents of the camel milk polypeptide, the oil phase, the stabilizer, the antioxidant, the thickening agent, the sweetening agent and the preservative are in the range, if the content of the emulsifier component is lower than 1.0 part, the oral liquid is unstable, and the water phase and the oil phase are easy to separate; if the content of the emulsifier component is higher than 2.5 parts, the emulsion is subjected to a phenomenon of deflocculation and is layered to form a precipitate; therefore, it is desirable that the content of the emulsifier component is 1.0 to 2.5 parts, preferably 1.6 to 2.0 parts;
when the contents of the camel milk polypeptide, the oil phase, the emulsifier, the antioxidant, the thickening agent, the sweetening agent and the preservative are in the range, if the content of the stabilizer component is lower than 0.01 part, the oral liquid is easy to delaminate and generate a precipitation phenomenon; if the content of the stabilizer component is higher than 0.05 part, the oral liquid is too viscous, so that the taste of the oral liquid is influenced; accordingly, a content of the stabilizer component of 0.01 to 0.05 parts is suitable, preferably 0.02 to 0.04 parts;
when the contents of the camel milk polypeptide, the oil phase, the emulsifier, the stabilizer, the thickening agent, the sweetening agent and the preservative are in the range, if the content of the antioxidant component is lower than 0.01 part, the oral liquid is easy to generate oxidative deterioration; if the content of the antioxidant component is more than 0.05 part, the oral liquid is too viscous, and the cost is also increased; accordingly, the content of the antioxidant component is suitably 0.01 to 0.05 parts, preferably 0.02 to 0.03 parts;
when the contents of the camel milk polypeptide, the oil phase, the emulsifier, the stabilizer, the antioxidant, the sweetener and the preservative are in the range, if the content of the thickener component is lower than 0.01 part, the prepared oral liquid is thinner and has uneven texture; if the content of the thickener component is higher than 0.05 part, the oral liquid is too viscous, and the tissue state of the oral liquid is influenced; therefore, it is desirable that the content of the thickener component is 0.01 to 0.05 parts, preferably 0.018 to 0.042 parts;
when the contents of the camel milk polypeptide, the oil phase, the emulsifier, the stabilizer, the antioxidant, the thickener and the preservative are in the range, if the content of the sweetener component is lower than 0.01 part, the oral liquid has light sweet taste and heavy citric acid taste, and the taste is too acid to influence the quality; if the content of the sweetening agent component is higher than 0.05 part, the oral liquid is too sweet and greasy, so that the experience effect of people is influenced; accordingly, the content of the sweetener component is suitably 0.01 to 0.05 parts, preferably 0.02 to 0.04 parts;
when the contents of the camel milk polypeptide, the oil phase, the emulsifier, the stabilizer, the antioxidant, the thickening agent and the sweetener are in the range, if the content of the preservative component is lower than 0.01 part, the preservative effect on the oral liquid is not obvious; if the content of the preservative component is more than 0.05 parts, there is an adverse effect on the physical health of the user; accordingly, the content of the preservative component is suitably 0.01 to 0.05 parts, preferably 0.02 to 0.04 parts;
preferably, the camel milk polypeptide nanoparticle oral liquid comprises the following components: in parts by weight
The invention also relates to a preparation method of the camel milk polypeptide nano-particle oral liquid.
The preparation method comprises the following preparation steps:
A. preparing camel milk polypeptide nanoparticles:
dissolving 0.012-0.020 part by weight of camel milk polypeptide in 1.5-2.5 parts by weight of mixed solvent consisting of ammonia water and absolute ethyl alcohol according to a weight ratio of 1:0.5 to obtain a camel milk polypeptide solution; heating 0.002-2.0 parts by weight of oil phase to 80 ℃, adding the camel milk polypeptide solution, uniformly mixing, heating at 75-80 ℃ to remove ammonia and ethanol, adding 1.0-2.5 parts by weight of emulsifier, stirring and uniformly mixing at 75-80 ℃, homogenizing for 6-8 min by using a homogenizing device at a homogenizing speed of 8000-12000 r/min, standing, and performing ultrasonic treatment by using an ultrasonic probe device to obtain the camel milk polypeptide nanoparticles; the camel milk polypeptide, oil phase and emulsifier have been described and will not be described in detail.
In this step, the essential role of the rest is to remove the excess air bubbles from the nanoparticles and to stabilize the emulsion texture.
The homogenisation equipment used in this step and in the subsequent steps is a product commonly used in the art and currently marketed, for example by the Shanghai Frank fluid machinery manufacturing company under the trade name FLUKO Frank.
The ultrasonic probe apparatus used in this step is a product currently on the market, such as a product sold under the trade name of ultrasonic cell disruptor by Nanjing Xinchen Biotechnology Ltd, and ultrasonic treatment is performed according to the method described in the instruction manual for use of the ultrasonic probe apparatus.
The detection is determined by adopting an ultrafiltration membrane filtration-indirect method standard detection method, the product obtained in the step is camel milk polypeptide nano particles, and the specific detection method is shown in the literature: wuqi, entitled "preparation of antioxidant egg white peptide liposome and research and development of its product", master school thesis of Jilin university, in 2018, month 08.
B. Preparation of an aqueous mixture
Mixing 0.01-0.05 part by weight of stabilizer, 0.01-0.05 part by weight of antioxidant, 0.01-0.05 part by weight of thickener, 0.01-0.05 part by weight of sweetener, 0.01-0.05 part by weight of preservative and deionized water which is supplemented to 100 parts by weight of the total amount, stirring and dissolving, homogenizing for 6-8 min under the condition that the homogenizing speed is 8000-12000 r/min, and standing to obtain an aqueous phase mixture;
the stabilizer, antioxidant, thickener, sweetener and preservative have been described and will not be described herein.
In this step, the basic effect of the rest is to disperse the oral liquid uniformly.
C. Mixing
And C, pouring the camel milk polypeptide nano-particles obtained in the step A into the water phase mixture obtained in the step B under the stirring condition, and continuously stirring for 2-5 minutes at the stirring speed of 15-25 r/min to obtain the camel milk polypeptide nano-particle oral liquid.
The camel milk polypeptide nanoparticle oral liquid has the following characteristics according to DPP4 inhibitory activity determination (Tanbei et al, entitled "influence of calcium and aluminum metal element chelation on oat polypeptide DPP4 inhibitory activity"; Chinese food and Nutrition, 2018, 24(05), pages 38-42) and standard methods for alpha-amylase inhibitory activity (see literature: Dasyin et al, entitled "inhibition of alpha-glucosidase and alpha-amylase by extracts from different parts of maize"; food industry science, 2021, 42(01), pages 15-21 and 27):
the camel milk polypeptide nano-particle oral liquid has good blood sugar reducing effect and is suitable for being taken by diabetes patients.
These properties completely meet the requirements of GB7101-2015 national standard for food safety beverage.
[ advantageous effects ]
The invention has the following beneficial effects:
the camel milk polypeptide nano-particle oral liquid disclosed by the invention is soft and refreshing in mouth feel, and free of astringent taste and pungent taste. Slightly sweet and sweet. The camel milk polypeptide nanoparticle oral liquid is transparent and uniform in color, colorless, uniform in tissue, free of layering and precipitation, has a good blood sugar reducing effect, and can effectively prevent and assist in treating diabetes.
[ detailed description ] embodiments
The invention will be better understood from the following examples.
Example 1: preparation of camel milk polypeptide nano-particle oral liquid
The implementation steps of this example are as follows:
A. preparing camel milk polypeptide nanoparticles:
dissolving 0.018 weight part of camel milk polypeptide in 2 weight parts of mixed solvent consisting of ammonia water and absolute ethyl alcohol according to the weight ratio of 1:0.5 to obtain a camel milk polypeptide solution; heating 0.002 weight part of glyceryl distearate oil phase to 80 ℃, adding the camel milk polypeptide solution, uniformly mixing, heating at 75 ℃ to remove ammonia and ethanol, adding 2.0 weight part of tween 80 emulsifier, stirring and uniformly mixing at 75 ℃, homogenizing for 6min at a homogenization speed of 10000r/min by using a homogenizing device, standing, and performing ultrasonic treatment by using an ultrasonic probe device to obtain the camel milk polypeptide nanoparticles;
the detection is determined by adopting an ultrafiltration membrane filtration-indirect method standard detection method, and the product obtained in the step is camel milk polypeptide nano-particles.
B. Preparation of an aqueous mixture
Mixing 0.05 part by weight of xanthan gum stabilizer, 0.01 part by weight of vitamin E antioxidant, 0.02 part by weight of sodium carboxymethylcellulose thickener, 0.03 part by weight of erythritol sweetener, 0.03 part by weight of potassium sorbate preservative and deionized water supplemented to the total amount of 100 parts by weight, stirring for dissolution, homogenizing for 6min at the homogenization speed of 8000r/min by using a homogenizing device, and standing to obtain an aqueous phase mixture;
C. mixing
And C, pouring the camel milk polypeptide nano-particles obtained in the step A into the water phase mixture obtained in the step B under the condition of stirring, and continuously stirring for 2 minutes at the stirring speed of 15r/min to obtain the camel milk polypeptide nano-particle oral liquid.
According to the DPP4 inhibitory activity determination and alpha-amylase inhibitory activity determination standard method, the camel milk polypeptide nanoparticle oral liquid has the following characteristics:
the camel milk polypeptide nano-particle oral liquid has good blood sugar reducing effect and is suitable for being taken by diabetes patients.
Example 2: preparation of camel milk polypeptide nano-particle oral liquid
The implementation steps of this example are as follows:
A. preparing camel milk polypeptide nanoparticles:
dissolving 0.012 part by weight of camel milk polypeptide in 2.5 parts by weight of mixed solvent consisting of ammonia water and absolute ethyl alcohol according to the weight ratio of 1:0.5 to obtain a camel milk polypeptide solution; heating 1.0 part by weight of oleic acid oil phase to 80 ℃, adding the camel milk polypeptide solution, uniformly mixing, heating at 80 ℃ to remove ammonia and ethanol, adding 1.0 part by weight of poloxamer 188 emulsifier, uniformly stirring and mixing at 80 ℃, homogenizing for 7min at a homogenization speed of 8000r/min by using a homogenizing device, standing, and performing ultrasonic treatment by using an ultrasonic probe device to obtain the camel milk polypeptide nanoparticles;
the detection is determined by adopting an ultrafiltration membrane filtration-indirect method standard detection method, and the product obtained in the step is camel milk polypeptide nano-particles.
B. Preparation of an aqueous mixture
Mixing 0.01 part by weight of carrageenan stabilizer, 0.05 part by weight of astaxanthin antioxidant, 0.01 part by weight of pectin thickener, 0.04 part by weight of glycerin sweetener, 0.01 part by weight of citric acid preservative and deionized water which is supplemented to the total amount of 100 parts by weight, stirring and dissolving, homogenizing for 7min at the homogenizing speed of 9000r/min by using a homogenizing device, and standing to obtain an aqueous phase mixture;
C. mixing
And C, pouring the camel milk polypeptide nano-particles obtained in the step A into the water phase mixture obtained in the step B under the condition of stirring, and continuously stirring for 3 minutes at the stirring speed of 18r/min to obtain the camel milk polypeptide nano-particle oral liquid.
According to the DPP4 inhibitory activity determination and alpha-amylase inhibitory activity determination standard method, the camel milk polypeptide nanoparticle oral liquid has the following characteristics:
the camel milk polypeptide nano-particle oral liquid has good blood sugar reducing effect and is suitable for being taken by diabetes patients.
Example 3: preparation of camel milk polypeptide nano-particle oral liquid
The implementation steps of this example are as follows:
A. preparing camel milk polypeptide nanoparticles:
dissolving 0.014 parts by weight of camel milk polypeptide in 1.5 parts by weight of mixed solvent composed of ammonia water and absolute ethyl alcohol according to the weight ratio of 1:0.5 to obtain a camel milk polypeptide solution; heating 0.10 part by weight of a mixture (weight ratio is 1:1) of glyceryl distearate and oleic acid to 80 ℃, adding the camel milk polypeptide solution, uniformly mixing, heating at 78 ℃ to remove ammonia and ethanol, adding 1.6 parts by weight of a mixture (weight ratio is 2:1) of tween 80 and polysorbate 80 as an emulsifier, uniformly stirring and mixing at 78 ℃, homogenizing for 8min at a homogenizing speed of 9000r/min by using a homogenizing device, standing, and performing ultrasonic treatment by using an ultrasonic probe device to obtain the camel milk polypeptide nanoparticles;
the detection is determined by adopting an ultrafiltration membrane filtration-indirect method standard detection method, and the product obtained in the step is camel milk polypeptide nano-particles.
B. Preparation of an aqueous mixture
Mixing 0.02 part by weight of xanthan gum and carrageenan mixture (weight ratio 2:3) stabilizer, 0.03 part by weight of vitamin E and astaxanthin mixture (weight ratio 1:3) antioxidant, 0.05 part by weight of carboxymethylcellulose sodium and acacia gum mixture (weight ratio 1:1) thickener, 0.01 part by weight of erythritol and glycerol mixture (weight ratio 1:4) sweetener, 0.04 part by weight of potassium sorbate and citric acid mixture (weight ratio 2:1) preservative and deionized water which is supplemented to the total amount of 100 parts by weight, stirring and dissolving, homogenizing for 8min at the homogenization speed of 10000r/min by using a homogenizing device, and standing to obtain an aqueous phase mixture;
C. mixing
And C, pouring the camel milk polypeptide nano-particles obtained in the step A into the water phase mixture obtained in the step B under the condition of stirring, and continuously stirring for 4 minutes at the stirring speed of 22r/min to obtain the camel milk polypeptide nano-particle oral liquid.
According to the DPP4 inhibitory activity determination and alpha-amylase inhibitory activity determination standard method, the camel milk polypeptide nanoparticle oral liquid has the following characteristics:
the camel milk polypeptide nano-particle oral liquid has good blood sugar reducing effect and is suitable for being taken by diabetes patients.
Example 4: preparation of camel milk polypeptide nano-particle oral liquid
The implementation steps of this example are as follows:
A. preparing camel milk polypeptide nanoparticles:
dissolving 0.020 weight part of camel milk polypeptide in 1 weight part of ammonia water and absolute ethyl alcohol according to a weight ratio of 1: 0.25 to obtain a camel milk polypeptide solution; heating 2.0 parts by weight of glyceryl distearate, a mixture of oleic acid and glyceryl monostearate (weight ratio is 2:1:1) to 80 ℃, adding the camel milk polypeptide solution, mixing uniformly, heating at 77 ℃ to remove ammonia and ethanol, adding 2.5 parts by weight of tween 80 and a phospholipid mixture (weight ratio is 2:3) emulsifier, stirring and mixing uniformly at 77 ℃, homogenizing by using a homogenizing device at a homogenizing speed of 12000r/min for 7min, standing, and performing ultrasonic treatment by using an ultrasonic probe device to obtain the camel milk polypeptide nanoparticles;
the detection is determined by adopting an ultrafiltration membrane filtration-indirect method standard detection method, and the product obtained in the step is camel milk polypeptide nano-particles.
B. Preparation of an aqueous mixture
Mixing 0.04 part by weight of xanthan gum and guar gum mixture (weight ratio of 3:1) stabilizer, 0.04 part by weight of vitamin E and tea polyphenol mixture (weight ratio of 1:1) antioxidant, 0.04 part by weight of carboxymethylcellulose sodium and gelatin mixture (weight ratio of 2:3) thickener, 0.05 part by weight of erythritol, glycerol and maltitol, mixture (weight ratio of 1:2:1) sweetener, 0.05 part by weight of potassium sorbate, citric acid and sodium benzoate mixture (weight ratio of 2:1:3) preservative and deionized water which is supplemented to the total amount of 100 parts by weight, stirring and dissolving, homogenizing for 7min under the condition that the homogenizing speed is 12000r/min by using a homogenizing device, and obtaining an aqueous phase mixture;
C. mixing
And C, pouring the camel milk polypeptide nano-particles obtained in the step A into the water phase mixture obtained in the step B under the condition of stirring, and continuously stirring for 5 minutes at the stirring speed of 25r/min to obtain the camel milk polypeptide nano-particle oral liquid.
According to the DPP4 inhibitory activity determination and alpha-amylase inhibitory activity determination standard method, the camel milk polypeptide nanoparticle oral liquid has the following characteristics:
the camel milk polypeptide nano-particle oral liquid has good blood sugar reducing effect and is suitable for being taken by diabetes patients.
Test example 1: the physical and chemical indexes of the camel milk polypeptide nano-particle oral liquid are tested
The experiment is based on the preparation of bovine serum albumin-dextran nanoparticles and the study on the embedding effect of the bovine serum albumin-dextran nanoparticles on the egg white source active peptide. (Cumin, preparation of bovine serum albumin-glucan nanoparticles and research on embedding effect of nanoparticles on egg white source active peptide [ D ]. Jilin university, 2019.)
Test items:
1. trait detection
The method comprises the following steps of (1) carrying out character detection under the room temperature condition by adopting a sensory evaluation method (preparation of bovine serum albumin-glucan nanoparticles and embedding effect research of the bovine serum albumin-glucan nanoparticles on egg white source active peptides, and sensitization, preparation of bovine serum albumin-glucan nanoparticles and embedding effect research of the bovine serum albumin-glucan nanoparticles on egg white source active peptides [ D ] Jilin university, 2019 ]):
the camel milk polypeptide nanoparticle oral liquid is transparent, uniform, colorless, has light sweet taste, has no pungent peculiar smell, is soft and tasty in taste, is slightly sweet and sweet, has uniform tissues, and does not have the phenomenon of layered precipitation.
2. Centrifugal test
The camel milk polypeptide nanoparticle oral liquid is packaged in a centrifuge tube by using a centrifuge sold by German Ebende GmbH under the trade name of a high-speed refrigerated centrifuge, and is centrifuged for 30min at the rotation speed of 4000r/min, and no layering phenomenon is found.
3. Stability test
The camel milk polypeptide nano-particle oral liquid is kept stand at room temperature in a dark place, and is transparent and uniform in color and luster, good in tissue state and free of obvious precipitation and stratification phenomenon in 1 month.
Test example 2: sensory evaluation test of camel milk polypeptide nanoparticle oral liquid
10 testers were randomly selected according to the sensory evaluation criteria for the quality of the camel milk polypeptide nanoparticle oral liquid described below, and sensory evaluation was performed on the camel milk polypeptide nanoparticle oral liquid prepared in examples 1 to 4.
Color grading standard: uniform and colorless color
Taste scoring standard: moderate sweet and sour, no peculiar smell
Tissue status scoring criteria: clear and transparent without sediment
Each score was given a 5-level score: score 5 is good and satisfactory; 4, the division is better; 3 is acceptable; when the amount is less than 3 points, the results are not acceptable. The scores were averaged, and the results are shown in Table 1.
Table 1: sensory evaluation result of camel milk polypeptide nanoparticle oral liquid
The results listed in table 1 clearly show that the camel milk polypeptide nanoparticle oral liquid is transparent and uniform, has soft mouthfeel, is slightly sweet and sweet, and has good tissue state.
In conclusion, the camel milk polypeptide nanoparticle oral liquid prepared by the invention is green and healthy, transparent and uniform in color, colorless, soft and tasty in taste, slightly sweet and sweet, free of pungent odor, uniform in tissue, free of layering and precipitation, and has a good blood sugar reducing effect. The camel milk polypeptide serving as the main raw material is wrapped by the solid lipid nanoparticles, so that the camel milk polypeptide can be better absorbed by a human body, the damage of gastrointestinal digestive juice to the peptide is avoided, and the bioavailability of the peptide is improved.
Claims (11)
1. A camel milk polypeptide nanoparticle oral liquid is characterized by comprising the following components: in parts by weight
2. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the camel milk polypeptide nanoparticle oral liquid comprises the following components: in parts by weight
3. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the camel milk polypeptide is camel milk polypeptide with a molecular weight of less than 3Kda obtained by enzymolysis and ultrafiltration of camel milk.
4. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the oil phase is one or more oil phases selected from the group consisting of glyceryl distearate, ethyl linoleate, glyceryl monostearate and oleic acid.
5. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the emulsifier is one or more selected from tween 80, poloxamer 188, phospholipids or polysorbate 80.
6. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the stabilizer is one or more selected from xanthan gum, guar gum, carrageenan, and agar.
7. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the thickening agent is one or more thickening agents selected from sodium carboxymethylcellulose, pectin, gelatin, and acacia.
8. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the antioxidant is one or more antioxidants selected from the group consisting of vitamin E, astaxanthin, tea polyphenol, and propyl gallate.
9. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the sweetener is one or more selected from erythritol, maltitol, xylitol, and glycerol.
10. The camel milk polypeptide nanoparticle oral liquid of claim 1, wherein the preservative is one or more preservatives selected from potassium sorbate, sodium benzoate, ethyl paraben, or citric acid.
11. The preparation method of the camel milk polypeptide nanoparticle oral liquid according to any one of claims 1 to 10, wherein the preparation method comprises the following steps:
A. preparing camel milk polypeptide nanoparticles:
dissolving 0.012-0.020 part by weight of camel milk polypeptide in 1.5-2.5 parts by weight of mixed solvent consisting of ammonia water and absolute ethyl alcohol according to a weight ratio of 1:0.5 to obtain a camel milk polypeptide solution; heating 0.002-2.0 parts by weight of oil phase to 80 ℃, adding the camel milk polypeptide solution, uniformly mixing, heating at 75-80 ℃ to remove ammonia and ethanol, adding 1.0-2.5 parts by weight of emulsifier, stirring and uniformly mixing at 75-80 ℃, homogenizing for 6-8 min by using a homogenizing device at a homogenizing speed of 8000-12000 r/min, standing, and performing ultrasonic treatment by using an ultrasonic probe device to obtain the camel milk polypeptide nanoparticles;
B. preparation of an aqueous mixture
Mixing 0.01-0.05 part by weight of stabilizer, 0.01-0.05 part by weight of antioxidant, 0.01-0.05 part by weight of thickener, 0.01-0.05 part by weight of sweetener, 0.01-0.05 part by weight of preservative and deionized water which is supplemented to 100 parts by weight of the total amount, stirring and dissolving, homogenizing for 6-8 min under the condition that the homogenizing speed is 8000-12000 r/min, and standing to obtain an aqueous phase mixture;
C. mixing
And C, pouring the camel milk polypeptide nano-particles obtained in the step A into the water phase mixture obtained in the step B under the stirring condition, and continuously stirring for 2-5 minutes at the stirring speed of 15-25 r/min to obtain the camel milk polypeptide nano-particle oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110687025.3A CN113498864A (en) | 2021-06-21 | 2021-06-21 | Camel milk polypeptide nano-particle oral liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110687025.3A CN113498864A (en) | 2021-06-21 | 2021-06-21 | Camel milk polypeptide nano-particle oral liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113498864A true CN113498864A (en) | 2021-10-15 |
Family
ID=78010497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110687025.3A Pending CN113498864A (en) | 2021-06-21 | 2021-06-21 | Camel milk polypeptide nano-particle oral liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113498864A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199481A (en) * | 2007-10-17 | 2008-06-18 | 浙江工业大学 | Process for preparing solid lipide nano particle |
| CN102258475A (en) * | 2010-05-28 | 2011-11-30 | 中国科学院上海药物研究所 | Daidzein solid lipid nanoparticles and preparation method thereof |
| CN103960727A (en) * | 2014-05-12 | 2014-08-06 | 天津商业大学 | Lycium ruthenicum beverage and preparation method thereof |
| CN104323281A (en) * | 2014-11-23 | 2015-02-04 | 福州乾正药业有限公司 | Aqueous piny flower and poria cocos composition as well as preparation method and application of aqueous piny flower and poria cocos composition |
| US20150290131A1 (en) * | 2012-10-25 | 2015-10-15 | Nestec S.A. | Encapsulated bitter peptides, methods of encapsulating bitter peptides, and nutritional compositions including encapsulated bitter peptides |
| CN108403612A (en) * | 2018-06-04 | 2018-08-17 | 内蒙古骆驼研究院 | It is a kind of to have effects that newborn facial treatment milk of the camel of resisting oxidation and delaying senility and preparation method thereof |
| CN109169923A (en) * | 2018-10-16 | 2019-01-11 | 内蒙古农业大学 | Hunchbacked milk beverage and preparation method thereof |
-
2021
- 2021-06-21 CN CN202110687025.3A patent/CN113498864A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199481A (en) * | 2007-10-17 | 2008-06-18 | 浙江工业大学 | Process for preparing solid lipide nano particle |
| CN102258475A (en) * | 2010-05-28 | 2011-11-30 | 中国科学院上海药物研究所 | Daidzein solid lipid nanoparticles and preparation method thereof |
| US20150290131A1 (en) * | 2012-10-25 | 2015-10-15 | Nestec S.A. | Encapsulated bitter peptides, methods of encapsulating bitter peptides, and nutritional compositions including encapsulated bitter peptides |
| CN103960727A (en) * | 2014-05-12 | 2014-08-06 | 天津商业大学 | Lycium ruthenicum beverage and preparation method thereof |
| CN104323281A (en) * | 2014-11-23 | 2015-02-04 | 福州乾正药业有限公司 | Aqueous piny flower and poria cocos composition as well as preparation method and application of aqueous piny flower and poria cocos composition |
| CN108403612A (en) * | 2018-06-04 | 2018-08-17 | 内蒙古骆驼研究院 | It is a kind of to have effects that newborn facial treatment milk of the camel of resisting oxidation and delaying senility and preparation method thereof |
| CN109169923A (en) * | 2018-10-16 | 2019-01-11 | 内蒙古农业大学 | Hunchbacked milk beverage and preparation method thereof |
Non-Patent Citations (9)
| Title |
|---|
| MINGZHU SHANGGUAN，等: "Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin", 《JOURNAL OF BIOMATERIALS APPLICATIONS》 * |
| UMA SHUKLA DUBEY，等: "Therapeutic potential of camel milk", 《EMIRATES JOURNAL OF FOOD AND AGRICULTURE.》 * |
| 何军，等: "水飞蓟素固体脂质纳米粒体内药代动力学研究", 《中成药》 * |
| 姜孙旻，等: "亲水性蛋白和多肽固体脂质纳米粒的制备方法", 《中国现代应用药学》 * |
| 李双双，等: "活性多肽奶基质脂质体的制备及应用", 《国际药学研究杂志》 * |
| 李湘斌，等: "胰岛素多肽固体脂质纳米粒的制备与理化性质研究", 《中国现代医学杂志》 * |
| 苏娜，等: "驼乳蛋白α-淀粉酶抑制活性肽的制备与鉴定", 《食品科学》 * |
| 苏莉晶: "固体脂质纳米颗粒增强燕麦多肽在胃肠道中对二肽基肽酶Ⅳ的抑制作用", 《中国优秀博硕士学位论文全文数据库(硕士)》 * |
| 高敏: "驼乳多肽固体脂质纳米颗粒的制备及其产品的开发", 《中国优秀博硕士学位论文全文数据库(硕士)》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103504293B (en) | Liquid nutritional composition | |
| EP2417970B1 (en) | Coenzyme q10 nanoparticles, preparation method thereof and composition containing said nanoparticles | |
| EP2298282B1 (en) | Combination of drugs having different physical properties into single dosage form | |
| JPH07507327A (en) | Nutritional formulations for humans with nervous system damage | |
| CN107969506A (en) | A kind of high stability fish oil breast for improving glycometabolism and preparation method thereof | |
| CN112839670A (en) | Ingestible formulations | |
| TWI592153B (en) | Methods of promoting the healing of diabetic ulcers using beta-hydroxy-beta-methylbutyrate with arginine and glutamine | |
| JPH0747544B2 (en) | O / W emulsion nutritional composition | |
| TWI749451B (en) | Pharmaceutical composition comprising omega fatty acids, and infusion preparation comprising the same | |
| US20060292226A1 (en) | Fatty emulsion injection of seal oil, method for preparation and the use in manufacturing intravenous injection | |
| JPH0393717A (en) | Derived pharmaceutical composition based on biological cell or component of biological cell and method for derivation thereof | |
| CN105770078B (en) | Pharmaceutical composition, preparation and application thereof | |
| CN113498864A (en) | Camel milk polypeptide nano-particle oral liquid and preparation method thereof | |
| TWI693898B (en) | Diluted nutritional composition | |
| CN113456592A (en) | Antiseptic and anti-inflammatory liposome and preparation method thereof | |
| JPH10251299A (en) | Fibroin fluid and its production | |
| CN112370425A (en) | Chlorophyll oral self-microemulsion preparation | |
| CN116158534B (en) | High-load and stable protein liposome | |
| CN112931738B (en) | Muscle protein thickening fluid beverage and preparation method thereof | |
| US20100173014A1 (en) | Methods of making and using nano scale particles | |
| CN114246331B (en) | Full-nutrition formula food suitable for special medical purpose of chronic obstructive pulmonary disease patient | |
| CN103768132B (en) | Pharmaceutical composition containing water-soluble vitamins for injection, fat-soluble vitamin injection and medium/long-chain fat emulsion injection | |
| CN107320468A (en) | Composite phospholipid liposome oral liquid and its preparation method and application | |
| US20220151275A1 (en) | Dietary Supplement for Gastrointestinal Inflammation and Method for Making the Same | |
| WO2021261545A1 (en) | Liquid food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211015 |